Oventus CEO and founder, Dr Chris Hart presented last week, providing an update to investors on Oventus’ progress and discussing our strategic response to COVID-19.
During the presentation, Dr Hart discusses:
- An overview of Obstructive Sleep Apnoea (OSA)
- The significant market opportunity in treating OSA patients who are underserved by existing therapies
- A summary of Oventus lab in lab business model, including the recent uptake in contracts with major sleep groups,
- Oventus’ strategic response to COVID-19, which includes use of telehealth and other remote procedures; and
- The U.S. home-care model, which is in the late stages of development and expected to be rolled out in the U.S. shortly
Due to internet availability, the audio quality of the recorded presentation is of variable quality. This improves after the first two minutes.
To watch the presentation, click play below.
Any investors interested in a direct update are invited to contact Jane Lowe via jane.lowe@irdepartment.com.au or +61 411 117 774.
Leave a Reply